Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 8/4/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Jay R. Shapiro

Wrong Dr. Jay R. Shapiro?

Director of the Osteogenesis Impe...

Phone: (443) ***-****  
Email: s***@***.org
Kennedy Krieger Institute
707 North Broadway Suite 232
Baltimore , Maryland 21205
United States

Company Description: Internationally recognized for improving the lives of children and adolescents with disorders and injuries of the brain, spinal cord and musculoskeletal system, the...   more

Employment History

Board Memberships and Affiliations


  • M.D.
    Kennedy Krieger Institute
  • Boston University
71 Total References
Web References
OI Staff | The Osteogenesis Imperfecta Clinic at Kennedy Krieger Institute, 4 June 2015 [cached]
Jay R. Shapiro, MD Director of the Osteogenesis Imperfecta Clinic at Kennedy Krieger Institute Professor in the Department of Physical Medicine and Rehabilitation at Johns Hopkins University
Jay R. Shapiro, MD
Dr. Shapiro has dedicated more than 30 years to researching, caring for, and treating children and adults with OI. His expertise also covers OI infants and OI pregnancies. Dr. Shapiro works closely with physicians at Johns Hopkins Hospital as well as local physicians to coordinate each OI patient's care and long-term well-being.
Contact Information
Jay R. Shapiro, OI Program Director Kennedy Krieger Institute 801 North Broadway, Baltimore MD 21205 Telephone: 443-923-2703
OI Clinic Contact Information | The Osteogenesis Imperfecta Clinic at Kennedy Krieger Institute, 4 June 2015 [cached]
Jay R. Shapiro, Director Kennedy Krieger Institute 801 North Broadway, Baltimore MD 21205 Telephone: 443-923-2703
Staff Directory
Jay R. Shapiro, Director Telephone: 443-923-2703 Email:
Remedies to bone loss in space may benefit Earth patients first, 28 Nov 2001 [cached]
"These two groups, astronauts and paraplegic patients, experience bone and muscle loss in the same areas - the lower part of the trunk and the legs," said Dr. Jay Shapiro, bone loss team leader for the National Space Biomedical Research Institute (NSBRI). "The rate of bone loss in space is almost as profound as it is in spinal cord injury patients."
Through an NSBRI-funded study at the National Rehabilitation Hospital in Washington, Shapiro is testing a medication, zoledronate, to see if it can inhibit bone loss in spinal cord injury patients. The drug, produced by Novartis, is a bisphosphonate, a class of medication known to inhibit the activity of cells responsible for reabsorbing, or eating up, bone. Bisphosphonates are commonly used to slow down bone loss related to osteoporosis.
"Throughout our lives, new bone is formed and old bone is absorbed," said Shapiro, a professor of medicine at the Uniformed Services University of the Health Sciences. "Bisphosphonates inhibit the cycle of bone breakdown that occurs, keeping you from losing as much and allowing the bone-forming processes a little more breathing room."
More time for bone growth is crucial for persons experiencing acute bone loss.
"Fracture risk is extremely high in adults and children immobilized by spinal cord or brain injuries, strokes, neuromuscular disorders, or developmental disorders like spina bifida and cerebral palsy," Shapiro said.
"This particular medication is many times stronger than the treatments in common use," Shapiro said. "Current intravenous treatments must be taken every two-to-three months, and oral medications of this type are taken daily."
Measurements taken throughout the study will assess the medication's effectiveness and side effects. Patients will undergo bone density measurements, computer measurements of muscle and of bone structure and geometry, and blood and urine biochemical analyses.
"If we can show that the medication inhibits bone loss in spinal cord injury patients, then it is likely that it would be effective in space," Shapiro said.
"The magnitude of this [effect] has ..., 27 Feb 2013 [cached]
"The magnitude of this [effect] has led NASA to consider bone loss an inherent risk of extended space flights," says Dr. Jay Shapiro, team leader for bone studies at the National Space Biomedical Research Institute said in a press statement.
Earth & Sky : Radio Shows, 11 Jan 1999 [cached]
Dr. Jay Shapiro Team Leader
"The delay in regaining pre-flight bone mass quickly is a very significant issue," asserts Jay Shapiro, professor at the Uniformed Services University of the Health Sciences and head of the bone loss team of the National Space Biomedical Research Institute (NSBRI)."What happens to these cells?Why don't they come back?We don't have the foggiest idea," he notes.
Other People with the name "Shapiro":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.